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Background: Resection of liver metastases from neuroendocrine cancer (NEC) prolongs survival and
provides durable symptom relief. Not all hepatic lesions are amenable to resection, particularly when there
is multifocal involvement. In this study, it was hypothesized that ablation of concomitant non-resectable
NEC liver metastases is safe and salvages patients who would not have been selected for cytoreductive
surgery.
Methods: Patients who underwent adjuvant ablation of NEC liver metastases between 1995 and 2008
were reviewed. NEC was classified by patient and tumour characteristics. Regression and Kaplan–Meier
models were used to compare variables and generate survival curves.
Results: Ninety-four patients underwent hepatic resection and intra-operative ablation of metastatic
NEC. The median number of lesions ablated was 3, and median size was 1.4 cm. One abscess occurred
at an ablation site. Local recurrence was detected in four patients (3.8%). Overall survival was 80% and
59% at 5 and 10 years. Age, gender, tumour type, grade, primary site and need for repeat ablation had
no significant association with survival. The Ki67 proliferative index was a significant predictor of
decreased survival. Symptom-free survival was 34% at 3 years and 16% at 5 years, independent of the
tumour grade.
Conclusion: Concurrent ablation of NEC metastases to the liver not amenable to resection is safe and
increases the candidacy of patients for cytoreductive surgery. Ablation performed intra-operatively and
repeated post-operatively as needed provides significant symptom control regardless of the tumour
grade.
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Introduction
Neuroendocrine cancers (NEC) are slow-growing epithelial neo-
plasms with predominant neuroendocrine differentiation. In spite
of their indolent course, more than half of the patients develop
hepatic metastases.1,2 Because of their low proliferative rate, cyto-
toxic chemotherapeutic agents are not effective against NEC.3
Similarly, somatostatin analogues that are used for symptom
control do not alter overall survival.4 Hence, surgical resection of
the primary tumour and hepatic metastases remain the mainstay
of treatment. In patients with hepatic metastases from NEC,
cytoreductive surgery improves symptom control, slows disease
progression and prolongs survival.5,6 Although the 5-year survival
of patients with unresectable liver metastases is about 30%,7 sur-
gical resection of these metastases prolongs 5-year survival to
60–80%.1,6
In spite of the apparent benefits of surgical resection, only
about 10% of patients with metastatic NEC to the liver are can-
didates for cytoreductive surgery8 owing to the extent or the loca-
tion of the liver metastases. Radiofrequency ablation (RFA) is an
additional method of liver-directed therapy. RFA of metastatic
NEC to the liver has been reported to provide 48% 5-year survival
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in patients with unresectable disease.9 To date, most reports of
RFA for metastatic NEC to the liver include patients that are
deemed unresectable9 or patients who underwent RFA after recur-
rence after resection.10 In this study, it was hypothesized that resec-
tion with adjunctive intra-operative RFA would increase the
number of candidates for cytoreductive surgery and provide more
complete cytoreduction. As a result, this combined treatment
strategy has not been incorporated into our practice.
Methods
This study was approved by the Mayo Clinic Institutional Review
Board. Ninety-eight consecutive patients who underwent com-
bined resection of metastatic NEC to the liver and intra-operative
RFA between January 1995 and December 2008 were identified
and their medical records reviewed. Four patients who were lost to
follow-up were excluded. All other patients were followed rou-
tinely with physical examination, radiological imaging (either
computerized tomography, magnetic resonance imaging or an
indium-111 octreotide scan), and laboratory evaluation including
serum hormone (in islet cell tumours) and 5-hydroxyindoleacetic
acid (5-HIAA) (in carcinoid tumours) levels. In post-operative
imaging, ablation sites were routinely assessed for evidence of
incomplete ablation.
The tumour burden in the liver was determined by pre-
operative imaging and confirmed routinely by intra-operative
ultrasonography. Two RFA systems were used over the time period
including those with a multitined electrode (StarBurst® Radiofre-
quency Ablation System; Angio Dynamics®, Latham, NY, USA)
and those with an internally cooled electrode (Cool-TipTM; Covi-
dien, Boulder, CO, USA). For lesions larger than 4 cm, the probe
was deployed multiple times to ensure complete destruction of
the tumour. The histopathology of resected metastases was
re-reviewed by an expert hepato-pathologist, who was unaware of
the clinical outcomes. The slides were stained with routine hae-
matoxylin and eosin and scored for tumour grade, number of
mitoses per high powered fields, angioinvasion and inflammation.
Immunohistochemistry for Ki67 was done on stored specimens of
90 patients, and the Ki67 index was determined by an automated
quantification method using the Automated Cellular Imaging
System III (Dako, Carpinteria, CA, USA).
Descriptive statistics are reported as number (percentage) or
either mean ( SD) or median (range) as appropriate. Post-
operative survival and symptom control were estimated using
Kaplan–Meier survival. Cox proportional hazards regression was
used to assess an univariate association of patient factors with
both overall survival and symptom control. The multivariate
analysis of overall survival was assessed using the a priori chosen
variables of primary disease (islet cell vs. carcinoid) and Ki67
index (3.5 vs. >3.5). Results of these models are reported as a
hazard ratio (HR) and a 95% confidence interval (CI). Categorical
variables were compared using Fisher’s exact test. The alpha-level
was set at 0.05 for statistical significance.
Results
Ninety-four patients with metastatic NEC who underwent com-
bined liver resection and ablation were reviewed (Table 1). There
were 41 men (43.6%) and 53 women (56.4%). The mean age was
53.7 years ( 1.6). Forty-eight patients (51.1%) had carcinoid
cancers and 46 (48.9%) had islet cell cancers. The most common
site of the origin of primary cancer was the pancreas (n = 44),
followed by the small bowel (n = 40), colon/rectum/appendix (n =
4), bronchus (n = 2), ovary (n = 1) and kidney (n = 1). The site of
the primary cancer was not found in two patients. Fifty-nine
patients (62.8%) had symptomatic endocrinopathies associated
with their tumour; 19 were on pre-operative somatostatin therapy
as a result of severe symptoms. Most NEC were intermediate to
high grade based on mitoses/high-power fields (HPF) and the
Ki67 index (Table 1). The median Ki67 index was 3.5%.
The majority of patients underwent hepatic segmentectomy or
subsegmentectomy (n = 70, 74.5%), whereas a hepatic lobectomy
was done in 18 patients (19.1%) (Table 2). Six patients (6.4%)
Table 1 Patient demographics and tumour characteristics
Age (years), mean  SD 53.7  11.6
Gender (M : F) 41 : 53
Primary disease, n (%)
Carcinoid 48 (51.1)
Islet cell 46 (48.9)
Non-functional 30 (31.9)
Gastrinoma 8 (8.5)
Insulinoma 4 (4.3)
Glucagonoma 3 (3.2)
VIPoma 1 (1.1)
Location of the primary disease, n (%)
Pancreas 44 (46.8)
Small bowel 40 (42.6)
Colon/rectum/appendix 4 (4.3)
Bronchus 2 (2.1)
Ovary 1 (1.1)
Kidney 1 (1.1)
Unknown 2 (2.1)
Pre-operative symptoms, n (%) 59 (62.8)
Pre-operative somatostatin, n (%) 19 (20.2)
Tumour histology
Mitoses, per 10 HPF (%)
<2 71 (75.5)
2 23 (24.5)
Ki67 index, n (%)
2 33 (35.1)
3–20 53 (56.4)
>20 4 (4.3)
HPF, high-power fields.
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underwent a bisegmentectomy. Intra-operative ultrasonography
was used routinely to confirm the metastases detected by pre-
operative imaging. A median of three metastases were ablated
intra-operatively (range: 1–14 per patient). The median size of
the ablated metastases was 1.4 cm (range: 0.3–8.0 cm). All
patients had near-total gross resection and ablation at the end of
the operation with minimal measurable residual disease. Quan-
tification of residual metastatic disease within the liver was pre-
cluded because accurate measurement intra-operatively was not
possible by imaging. There was no peri-operative mortality
(Table 3). One patient who had previously underwent a pancre-
aticoduodenectomy for the primary NEC developed an abscess at
an ablation site 2 weeks post-operatively that resolved after per-
cutaneous drainage.
Overall, in 57 out of 59 (96.6%) patients with pre-operative
symptoms, symptom relief was achieved after the operation. By 5
years, the cumulative probability of symptom recurrence was
84%, with a median time to recurrence of 2 years. Similarly, pro-
gression by imaging was seen in 86% of patients. Four patients
(4.2%) had tumour recurrence at the site of ablation. Twenty-one
(22%) patients underwent additional post-operative ablation for
metastatic progression at a median interval of 19 months post-
operatively (Table 3). The overall 5- and 10-year survivals were
80% and 59%, respectively (Fig. 1a).
Univariate regression models showed that age, gender, type and
site of the primary cancer were not significantly associated with
survival (Table 4). Similarly, repeat RFA of metastatic NEC during
the follow-up was not associated with survival. Of the histopatho-
logical characteristics of the metastases which were assessed, the
Ki67 index (3.5 relative to <3.5) was the most significant pre-
dictor for decreased survival in both univariate (HR = 4.28, CI
1.51–12.14, P = 0.006) and multivariate (HR = 5.01, CI 1.65–
15.18, P = 0.004) analyses. The Ki67 index (3.5 relative to <3.5)
had a borderline, although non-significant association with
symptom-free survival (HR = 1.53, CI 0.98–2.38, P = 0.06). Pre-
operative somatostatin analogue use correlated with decreased
symptom-free duration post-operatively (HR = 1.73, CI 1.04–
2.89, P = 0.03) (Table 5).
Discussion
The management of patients with metastatic NEC to the liver has
evolved over the past two decades. In the absence of effective
systemic therapy, liver-directed cytoreductive therapy is widely
accepted as the standard of care. Whether complete or near-total
operative cytoreduction is performed, resection provides the most
prolonged survival and durable control of symptomatic endo-
crinopathies.11 In 2003, we reported our single-centre experience,
in which resection of metastatic NEC to the liver in 170 patients
Table 2 Operative procures and characteristics of ablated lesions
Surgical resection, n (%)
Hepatic lobectomy 18 (19.1)
Bisegmentectomy 6 (6.4)
Segmentectomy/subsegmentectomy 70 (74.5)
Patients requiring additional post-operative RFA, n (%) 21 (22.3)
Number of lesions ablated, median (range) 3 (1–14)
Size of lesions ablated, cm, median (range) 1.4 (0.3–8)
RFA, radiofrequency ablation.
Table 3 Outcomes
Follow-up (months), mean  SD 58  36.9
Local complications
Abscess at the ablation site, n (%) 1 (1.1)
Recurrence at the ablation site, n 4
Tumour recurrence, n 81
Time to recurrence (months), median 19
Symptom-free survival (months), median 24
Figure 1 Overall (a), and symptom-free survival (b) of patients after
the combined resection and ablation. Actuarial survival estimates
are shown under each graph
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resulted in overall survival of 61% and 35% at 5- and 10-years,
respectively.6 In a recent multicentre international study of 339
patients who underwent liver-directed therapy of metastatic NEC
to the liver, overall 5- and 10-year survival were 74% and 51%,
respectively.5 Because resection alone of hepatic metastases can be
offered only to a subset of patients, ablation, either alone or in
conjunction with resection, has recently been introduced success-
fully as a treatment option for patients with metastatic NEC to the
liver. The rationale of combining these two modalities is that more
complete cytoreduction can be achieved with adjunctive ablation
in patients with extensive hepatic tumour burden or those with
deep-seated metastases in whom resection would risk an adequate
functional remnant. Hence resection and RFA could increase the
number of candidates for cytoreductive surgery and decrease the
overall risk of insufficient remnant volume. We have been using
ablation in combination with resection since 1995, and the
current series is the largest to our knowledge.
The present results demonstrate that the adjunctive ablation is
safe and well tolerated. Although not common, thermal injury to
bile ducts with subsequent stricturing12 or adjacent organs13
during percutaneous ablation of liver lesions have been reported.
Intra-operative ablation with the aid of real-time ultrasono-
graphic examination and protection of adjacent organs help
prevent both these potential complications. In the present cohort,
we have not had any complications secondary to thermal injury.
One patient (1.1%) had a local abscess at the site of ablation
detected by imaging 2 weeks post-operatively. This patient had a
previous pancreatoduodenectomy with a choledochoenteros-
tomy. The abscess resolved after percutaneous drainage with no
long-term sequela. In four patients (4.3%), we found local recur-
rence during follow-up, presumably as a result of incomplete abla-
tion. This incidence is lower than the 11% local recurrence
reported by Mazzaglia and colleagues9 in a 10-year experience of
laparoscopic RFA of metastatic NEC to the liver.
The overall 5-year and 10-year survival of 80% and 59%,
respectively, herein are greater than several previous reports by
others5,14 and us.6 However, these findings are inadequate to
support improved survival because of the retrospective design of
this study and the probability of accounted selection factors.
Although it is possible that more complete cytoreduction through
the addition of RFA accounts for these findings, quantification of
such was not possible owing to the limits of resolution of current
intra- and post-operative imaging. While a comparison of survival
among different patient groups and eras is difficult, it is notewor-
thy that most patients herein had intermediate to high grade NEC
which was unexpected given the overall survival. The proliferative
rate of NEC, as assessed by the mitotic rate and Ki67 index, has
Table 4 Risk factors associated with decreased survival
Univariate Multivariate
HR (95%CI) P HR (95% CI) P
Gender (M vs. F) 0.79 (0.32–1.95) 0.61
Age, per 1 year 1.00 (0.95–1.04) 0.86
Primary disease (islet cell vs. carcinoid) 1.21 (0.51–2.89) 0.66 0.67 (0.26–1.71) 0.40
Functional vs. non-functional (islet cell tumour) 0.95 (0.28–3.27) 0.94
Need for repeated RFA 1.31 (0.49–3.50) 0.59
Pre-operative octreotide 0.53 (0.12–2.28) 0.39
Tumour histology
Grade (Grade 2 vs. Grade 1) 2.30 (0.91–5.84) 0.08
Mitoses, per 1 unit 1.02 (0.99–1.05) 0.15
Angioinvasion (Yes vs. No) 2.06 (0.81–5.19) 0.18
Ki67 index (3.5 vs. <3.5) 4.28 (1.51–12.14) 0.006 5.01 (1.65–15.18) 0.004
Inflammation (Yes vs. No) 1.57 (0.46–5.38) 0.47
RFA, radiofrequency ablation.
Table 5 Risk factors associated with decreased symptom-free
survival
Univariate
HR (95%CI) P
Gender (M vs. F) 1.04 (0.68–1.58) 0.87
Age, per 1 year 0.98 (0.97–1.00) 0.13
Primary disease (islet cell vs. carcinoid) 1.38 (0.91–2.09) 0.13
Functional vs. non-functional
(islet cell tumour)
1.19 (0.69–2.06) 0.52
Need for repeated RFA 1.33 (0.83–2.13) 0.24
Preoperative octreotide 1.73 (1.04–2.89) 0.03
Tumour histology
Grade (Grade 2 vs. Grade 1) 1.02 (0.63–1.65) 0.94
Mitoses, per 1 unit 1.01 (0.99–1.02) 0.62
Angioinvasion (Yes vs. No) 1.17 (0.76–1.79) 0.48
Ki67 index ( 3.5 vs. < 3.5) 1.53 (0.98–2.38) 0.06
Inflammation (Yes vs. No) 1.52 (0.73–3.19) 0.26
RFA, radiofrequency ablation.
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been accepted by both the World Health Organization (WHO)
and the European Neuroendocrine Tumor Society (ENETS)
grading systems as the main determinant of tumour aggressive-
ness of NEC overall.15 We found that the high Ki67 index was the
most significant predictor of decreased survival in both univariate
and multivariate analyses, confirming earlier reports in patients
that underwent resection of primary16 or metastatic NEC,10 or
liver transplantation for metastatic NEC.17 Other histopathologi-
cal characteristics of NEC, such as mitoses, inflammation and
angioinvasion, had no significant association with survival. The
grade of the tumour conferred a 2.3 times higher risk of decreased
survival; however this did not reach statistical significance, possi-
bly because of the relatively small sample size. A high Ki67 index
was also associated with the probability of the need for repeated
RFA as more patients with a high index required repeated RFA
(Fisher’s exact test, P = 0.023).
Malignant endocrinopathies are common in patients with
metastatic NEC of the liver. In this study, it was demonstrated that
combined resection and RFA adequate symptom control was
achieved in 96.6% of our patients, similar to previously published
reports.5,6,18 Symptom recurrence with disease progression was
almost uniform in our patients because complete resection was
seldom feasible. The median symptom-free post-operative period
was 24 months (Fig. 1b). Not surprisingly, somatostatin analogue
therapy pre-operatively predicted a shorter symptom-free period
after cytoreduction. Importantly, tumour grade and the Ki67
index had no significant predictive impact on the symptom-free
survival. Consequently, we believe that these results provide
support for liver-directed therapy in all eligible candidates, regard-
less of the tumour biology.
Prior to incorporation of RFA to our surgical practice, only
patients in whom an expected near complete resectability based
on preoperative imaging were offered surgical treatment.19 We
have since relaxed that selection criteria and have shifted towards
more aggressive cytoreduction in patients with NEC. Because of
our inability to fully cull all patients with metastatic NEC who
had a surgical consultation, comparison of practice differences
between eras is not feasible retrospectively. Thus, we lack objec-
tive data to determine the ratio of patients who underwent
operative cytoreduction after surgical consultation. However, we
are convinced the present cohort includes patients who would
not have been offered resection prior to the incorporation of
RFA to our practice. The present study has several limitations
inherent to retrospective analyses. The patients represent a care-
fully selected cohort among the many with metastatic NEC. In
addition, the extent of metastatic involvement of the liver, which
may be used for selection of different treatment modalities,14,20
was not evaluated. In patients in whom near complete resection
is feasible, we continue to offer resection alone, even if selective
portal venous embolization is required to increase future liver
remnant volume.
In summary, our results show that the combined liver-directed
therapy of metastatic NEC to the liver can be done safely. Adjunc-
tive ablation of otherwise non-resectable metastatic NEC to the
liver complements cytoreductive resection and provides effective
but transient symptom control. Incorporation of RFA as an essen-
tial component of operative cytoreduction will expand selection
of patients for operation and potentially increase the durability of
response.
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